Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, vol.16, issue.5, pp.275-287, 2016. ,
, , p.27079802
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, vol.8, issue.3, 2006. ,
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem, vol.108, issue.1, pp.19-24, 2006. ,
,
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer, Proc Natl Acad Sci, vol.104, issue.9, pp.3360-3365, 2007. ,
, , p.17360651
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, vol.13, issue.7, pp.2151-2157, 2007. ,
, , p.17404099
Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest, vol.94, issue.1, p.24217091, 2014. ,
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, vol.515, issue.7528, p.25428507, 2014. ,
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma, Nat Med, vol.21, issue.1, 2015. ,
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, issue.6230, 2015. ,
vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov, vol.5, issue.1, p.25358689, 2015. ,
Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability, Immunity, vol.44, issue.3, 2016. ,
PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.372, issue.26, 2015. ,
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol, vol.18, issue.9, pp.30422-30431, 2017. ,
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, vol.410, issue.6832, 2001. ,
The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev, vol.13, issue.2, p.11900986, 2002. ,
Interferongamma and cancer immunoediting, Immunol Res, vol.32, p.16106075, 2005. ,
CD4 and CD8 T lymphocyte interplay in controlling tumor growth, Cell Mol Life Sci, vol.75, issue.4, 2018. ,
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, vol.313, issue.5795, 2006. ,
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res, vol.71, issue.4, 2011. ,
IFN-? from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer, Br J Cancer, vol.112, issue.9, 2015. ,
Interferon-?-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression, Oncoimmunology, vol.4, issue.6, 2015. ,
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells, Sci Transl Med, vol.5, 0200. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-567, 2014. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, 2016. ,
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade, J Clin Invest, vol.127, issue.8, 2017. ,
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients, Ther Adv Med Oncol, vol.10, 2018. ,
A novel transcription factor, T-bet, directs Th1 lineage commitment, Cell, vol.100, issue.6, p.10761931, 2000. ,
Antigen-driven effector CD8 T cell function regulated by T-bet, Proc Natl Acad Sci U S A, vol.100, issue.26, 2003. ,
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1)and increase expression after stimulation with IFNgamma and TLR ligands via a MyD88, TRAF6-, and MEK-dependent pathway, Blood, vol.110, issue.1, p.17363736, 2007. ,
Alternative activation of macrophages, Nat Rev Immunol, vol.3, issue.1, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00474829
Alternative activation of macrophages: mechanism and functions, Immunity, vol.32, issue.5, 2010. ,
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer, J Clin Oncol, vol.36, issue.8, 2018. ,
Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer, J Clin Oncol, vol.36, p.3514, 2018. ,
The Immunogenicity of colorectal cancer in relation to tumor development and treatment, Int J Mol Sci, vol.17, issue.7, 2016. ,
Helper activity is required for the in vivo generation of cytotoxic T cells, J Exp Med, vol.155, p.6801178, 1982. ,
The roles of CD4+ T cells in tumor immunity, ISRN Immunology, vol.497397, 2011. ,
Tumorreactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, J Exp Med, vol.207, issue.3, 2010. ,
The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors, J Natl Cancer Inst, vol.110, issue.1, p.28922790, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01727817
Characterization of an adaptive immune response in microsatellite-instable colorectal cancer, Oncoimmunology, vol.3, 2014. ,
The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer ,
, J Pathol Clin Res, vol.2, issue.1, 2015.
Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res, vol.75, issue.11, 2015. ,
Elements of cancer immunity and the cancer-immune set point, Nature, vol.541, issue.7637, 2017. ,
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature, J Clin Oncol, vol.33, 2015. ,
Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers, Br J Cancer, vol.115, issue.4, p.27404452, 2009. ,
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma, Mod Pathol, vol.29, issue.11, 2016. ,
PDL1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes, Mod Pathol, vol.29, issue.9, 2016. ,
Clinicopathologic profile, immunophenotype, and genotype of CD274(PD-L1)-positive colorectal carcinomas, Mod Pathol, vol.30, issue.2, p.27813511, 2017. ,
Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability, Int J Cancer, vol.142, issue.4, 2018. ,
PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments, Oncotarget, vol.9, issue.9, p.29492219, 2018. ,
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, vol.4, issue.127, 2012. ,
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma, Onco Targets Ther, vol.10, 2017. ,
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition, Clin Cancer Res, vol.19, issue.3, p.23095323, 2013. ,
Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment, Mod Pathol, vol.29, issue.5, pp.528-541, 2016. ,
,
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma, World J Gastroenterol, vol.22, issue.13, p.27053851, 2016. ,
Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene, J Biol Chem, vol.271, issue.29, p.8663541, 1996. ,
Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: interferon-gamma is the inducer, Adv Exp Med Biol, vol.294, p.1772076, 1991. ,
The rationale of indoleamine 2,3 dioxygenase inhibition for cancer therapy, Eur J Cancer, vol.76, 2017. ,
Medullary colorectal carcinoma revisited: a clinical and pathological study of 102 cases, Ann Surg Oncol, vol.22, issue.9, p.25572685, 2015. ,
Domainspecific PD-L1 protein measurement in non-small cell lung cancer (NSCLC), J Clin Oncol, vol.5, p.8064, 2014. ,
CD163: a specific marker of macrophages in paraffin-embedded tissue samples, Am J Clin Pathol, vol.122, issue.5, 2004. ,
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR, Gastroenterology, vol.123, issue.6, 2002. ,
Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, vol.96, issue.4, p.14970275, 2004. ,
Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven,IFN-gamma-mediated epithelial damage in human colon explants, J Clin Invest, vol.118, issue.3, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00277246
Loss ofinterleukin-10 or transforming growth factor ? signaling in the human colon initiates a T-helper 1 response via distinct pathways, Gastroenterology, vol.141, issue.5, pp.1887-96, 2011. ,
, , p.21839042
Cha SS Cutpoint determination methods in survival analysis using SAS®, Proceedings of the 28th SAS Users Group International Conference (SUGI), 2003. ,